Arcus Biosciences, Inc. — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 58/100
What the filing says
Arcus reported Q3 2026 net loss of $128M on $9M revenue (down from $26M YoY). Cash position declined to $694M from $1.010B at year-end 2025, but October 2026 equity financing added $288M gross proceeds, extending runway to 2029. Lead program casdatifan demonstrated encouraging efficacy data across kidney cancer: first-line casdatifan+zimberelimab achieved 86% PFS at 6 months; second-line casdatifan+cabozantinib showed median PFS 14.5 months vs benchmarks; late-line monotherapy showed median OS 35 months. PEAK-1 Phase 3 (second-line) enrollment expected complete in 2–3 months; PEAK-20 Phase 3 (first-line) initiation targeted Q4 2026. R&D expenses decreased to $117M from $141M YoY due to domvanalimab wind-down, offsetting increased casdatifan investment.
Why this rating
Positive: Strong clinical efficacy data supports casdatifan as material franchise; $288M financing secures 2+ years runway. Moderate significance: Early-stage Phase 3 data not yet Phase 3 outcomes; casdatifan revenue still $0; cash burn material (306M in 9mo) vs $566M market cap; success uncertain. Real but not transformational at this stage.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.